{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T18:12:34Z","timestamp":1747159954924,"version":"3.40.5"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["L'Enc\u00e9phale"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.encep.2024.04.001","type":"journal-article","created":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T03:08:08Z","timestamp":1723259288000},"page":"479-482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacological and nutraceutical treatments for borderline personality disorder"],"prefix":"10.1016","volume":"50","author":[{"given":"Cyril","family":"G\u00e9rolymos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Masson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3249-2030","authenticated-orcid":false,"given":"Guillaume","family":"Fond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.encep.2024.04.001_bib0140","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/wps.21156","article-title":"Borderline personality disorder: a comprehensive review of diagnosis and clinical presentation, etiology, treatment, and current controversies","volume":"23","author":"Leichsenring","year":"2024","journal-title":"World Psychiatry"},{"issue":"9","key":"10.1016\/j.encep.2024.04.001_bib0145","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40263-017-0458-4","article-title":"Efficacy and tolerability of asenapine compared with olanzapine in borderline personality disorder: an open-label randomized controlled trial","volume":"31","author":"Bozzatello","year":"2017","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.encep.2024.04.001_bib0150","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1001\/archpsyc.1988.01800260015002","article-title":"Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine","volume":"45","author":"Cowdry","year":"1988","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"10.1016\/j.encep.2024.04.001_bib0155","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1176\/appi.ajp.160.1.167","article-title":"Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study","volume":"160","author":"Zanarini","year":"2003","journal-title":"Am J Psychiatry"},{"issue":"6","key":"10.1016\/j.encep.2024.04.001_bib0160","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1080\/15622975.2021.2013041","article-title":"Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: the World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce","volume":"23","author":"Sarris","year":"2022","journal-title":"World J Biol Psychiatry"},{"issue":"11","key":"10.1016\/j.encep.2024.04.001_bib0165","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.4088\/JCP.v65n1112","article-title":"Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study","volume":"65","author":"Nickel","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.encep.2024.04.001_bib0170","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.biopsych.2004.11.044","article-title":"Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study","volume":"57","author":"Nickel","year":"2005","journal-title":"Biol Psychiatry"},{"issue":"1","key":"10.1016\/j.encep.2024.04.001_bib0175","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.jcp.0000195113.61291.48","article-title":"Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study","volume":"26","author":"Loew","year":"2006","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"10.1016\/j.encep.2024.04.001_bib0180","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1176\/ajp.2006.163.5.833","article-title":"Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled, study","volume":"163","author":"Nickel","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.encep.2024.04.001_bib0185","doi-asserted-by":"crossref","first-page":"38","DOI":"10.5455\/bcp.20140923100030","article-title":"A comparative study on olanzapine and aripiprazole for symptom management in female patients with borderline personality disorder","volume":"25","author":"Shafti","year":"2015","journal-title":"Bull Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.encep.2024.04.001_bib0190","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/0269881105051540","article-title":"Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study","volume":"19","author":"Tritt","year":"2005","journal-title":"J Psychopharmacol"},{"issue":"5","key":"10.1016\/j.encep.2024.04.001_bib0195","first-page":"270","article-title":"A preliminary study of lamotrigine in the treatment of affective instability in borderline personality, disorder","volume":"24","author":"Reich","year":"2009","journal-title":"Int Clin Psychopharmacol"},{"issue":"11","key":"10.1016\/j.encep.2024.04.001_bib0200","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4088\/JCP.v62n1103","article-title":"Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot, study","volume":"62","author":"Zanarini","year":"2001","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"10.1016\/j.encep.2024.04.001_bib0205","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1176\/appi.ajp.162.6.1221","article-title":"Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder","volume":"162","author":"Soler","year":"2005","journal-title":"Am J Psychiatry"},{"issue":"6","key":"10.1016\/j.encep.2024.04.001_bib0210","doi-asserted-by":"crossref","first-page":"999","DOI":"10.4088\/JCP.v69n0617","article-title":"Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot, study","volume":"69","author":"Linehan","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"10.1016\/j.encep.2024.04.001_bib0215","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1192\/bjp.bp.107.037903","article-title":"Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study","volume":"193","author":"Schulz","year":"2008","journal-title":"Br J Psychiatry"},{"issue":"10","key":"10.1016\/j.encep.2024.04.001_bib0220","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.4088\/JCP.08m04138yel","article-title":"A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study","volume":"72","author":"Zanarini","year":"2011","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"10.1016\/j.encep.2024.04.001_bib0225","doi-asserted-by":"crossref","first-page":"903","DOI":"10.4088\/JCP.v65n0704","article-title":"A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder","volume":"65","author":"Zanarini","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.encep.2024.04.001_bib0230","doi-asserted-by":"crossref","first-page":"5328","DOI":"10.1038\/s41380-023-02154-4","article-title":"How can we improve the care of patients with schizophrenia in the real-world? A population-based cohort study of 456,003 patients","volume":"28","author":"Fond","year":"2023","journal-title":"Mol Psychiatry"},{"issue":"11","key":"10.1016\/j.encep.2024.04.001_bib0235","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1176\/appi.ajp.2014.13101348","article-title":"Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: a randomized, double-blind, placebo-controlled trial","volume":"171","author":"Black","year":"2014","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.encep.2024.04.001_bib0240","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4088\/JCP.v65n0314","article-title":"Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder","volume":"65","author":"Simpson","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"10.1016\/j.encep.2024.04.001_bib0245","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/archpsyc.1997.01830240035005","article-title":"Fluoxetine and impulsive aggressive behavior in personality-disordered subjects","volume":"54","author":"Coccaro","year":"1997","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"10.1016\/j.encep.2024.04.001_bib0250","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1001\/archpsyc.1993.01820170055007","article-title":"Efficacy of phenelzine and haloperidol in borderline personality disorder","volume":"50","author":"Soloff","year":"1993","journal-title":"Arch Gen Psychiatry"},{"issue":"12","key":"10.1016\/j.encep.2024.04.001_bib0255","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1176\/ajp.150.12.1843","article-title":"Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine","volume":"150","author":"Cornelius","year":"1993","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.encep.2024.04.001_bib0260","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00004714-198908000-00002","article-title":"Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response","volume":"9","author":"Soloff","year":"1989","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"10.1016\/j.encep.2024.04.001_bib0265","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/sj.npp.1300153","article-title":"Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders","volume":"28","author":"Hollander","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.encep.2024.04.001_bib0270","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12884-018-1842-x","article-title":"Sodium valproate in pregnancy: what are the risks and should we use a shared decision-making approach?","volume":"18","author":"Macfarlane","year":"2018","journal-title":"BMC Pregnancy Childbirth"}],"container-title":["L'Enc\u00e9phale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700624001015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700624001015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T15:58:22Z","timestamp":1727193502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0013700624001015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0013700624001015"],"URL":"https:\/\/doi.org\/10.1016\/j.encep.2024.04.001","relation":{},"ISSN":["0013-7006"],"issn-type":[{"type":"print","value":"0013-7006"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological and nutraceutical treatments for borderline personality disorder","name":"articletitle","label":"Article Title"},{"value":"L'Enc\u00e9phale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.encep.2024.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 L'Enc\u00e9phale, Paris.","name":"copyright","label":"Copyright"}]}}